Ultrasonic RF time series for early assessment of the tumor response to chemotherapy
Metrics: PDF 421 views | HTML 954 views | ?
Qingguang Lin1,*, Jianwei Wang1,*, Qing Li1,*, Chunyi Lin2, Zhixing Guo1, Wei Zheng1, Cuiju Yan1, Anhua Li1 and Jianhua Zhou1
1Department of Ultrasound, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, P.R. China
2School of Electronic and Information Engineering, South China University of Technology, Guangzhou, 510640, P.R. China
*These authors have contributed equally to this work
Jianhua Zhou, email: firstname.lastname@example.org
Keywords: chemotherapy; cancer; ultrasonic radio-frequency time series; microstructure
Received: March 21, 2017 Accepted: December 15, 2017 Published: December 23, 2017
Ultrasound radio-frequency (RF) time series have been shown to carry tissue typing information. To evaluate the potential of RF time series for early prediction of tumor response to chemotherapy, 50MCF-7 breast cancer-bearing nude mice were randomized to receive cisplatin and paclitaxel (treatment group; n = 26) or sterile saline (control group; n = 24). Sequential ultrasound imaging was performed on days 0, 3, 6, and 8 of treatment to simultaneously collect B-mode images and RF data. Six RF time series features, slope, intercept, S1, S2, S3, and S4, were extracted during RF data analysis and contrasted with microstructural tumor changes on histopathology. Chemotherapy administration reduced tumor growth relative to control on days 6 and 8. Compared with day 0, intercept, S1, and S2 were increased while slope was decreased on days 3, 6, and 8 in the treatment group. Compared with the control group, intercept, S1, S2, S3, and S4 were increased, and slope was decreased, on days 3, 6, and 8 in the treatment group. Tumor cell density decreased significantly in the latter on day 3. We conclude that ultrasonic RF time series analysis provides a simple way to noninvasively assess the early tumor response to chemotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.